Docetaxel PhaRes 20 mg/vial (IV Infusion)

Indications

• Breast Cancer treatment as a single agent
• Adjuvant treatment for operable node-positive Breast Cancer
• Non-small Cell Lung Cancer treatment
• Castration-Resistant Prostate Cancer treatment
• Gastric Adenocarcinoma treatment
• Squamous Cell Carcinoma of the Head and Neck treatment

Pharmacology

• Acts by disrupting the microtubular network
• Promotes the assembly of tubulin into stable microtubules
• Inhibits the disassembly of microtubules

Dosage & Administration

• Administer intravenously over 1 hr every 3 weeks
• Dosage varies based on cancer type and treatment stage
• PVC equipment not recommended

Interaction

• CYP3A4 substrate
• Metabolism may be modified by concomitant administration of certain compounds

Contraindications

• Contraindicated in patients with neutrophil counts of <1500 cells/mm³
• History of severe hypersensitivity reactions to docetaxel or polysorbate 80

Side Effects

• Common adverse reactions include infections, neutropenia, anemia, hypersensitivity
• Adverse reaction incidence varies by indication

Pregnancy & Lactation

• Can cause fetal harm when administered to a pregnant woman
• No information on presence in human milk or effects on breastfeeding

Precautions & Warnings

• Higher risk of severe adverse reactions in patients with hepatic impairment
• Close monitoring required for severe hypersensitivity reactions
• Administered under the supervision of a physician experienced in antineoplastic agents

Overdose Effects

• No known antidote for docetaxel overdose
• Bone marrow suppression, peripheral neurotoxicity, and mucositis are anticipated complications

Therapeutic Class

• Cytotoxic Chemotherapy

Storage Conditions

• Store between 2°C and 25°C
• Protected from light
• Freezing does not adversely affect the product

Related Brands

• Taxodoc 20 mg/vial (IV Infusion) - renata-limited
• Taxodoc 80 mg/vial (IV Infusion) - renata-limited
• Daxotel 20 mg/vial (IV Infusion) - drug-international-ltd